Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Неэпителиальные опухоли яичников

Список литературы

  1. P., Genestie C. et al. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecol Oncol 2016;142:452-7.
  2. Matei D., Brown J., Frazier L. Updates in the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ Book 2013;e210.
  3. Давыдова И.Ю. Незрелые тератомы Gatta G., van der Zwan J.M., Casali P.G. et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011;47:2493-511.
  4. Prat J. Ovarian sex cord-stromal and steroid cell tumors (Chapter 28). In: Mutter G.L., Prat J., editors. Pathology of the Female Reproductive Tract. 3rd ed. Edinburgh: Churchill Livingstone (Elsevier); 2014.
  5. Gardener G.J., Reidy-Lagunes D., Gehrig P.A. et al. Neuroendocrine tumors of the gynecological tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 2011;122(1):190-8.
  6. Gershenson D.M. Current advances in the management of malignant germ cell and sex cord- stromal tumors of the ovary. Gynecol Oncol 2012;125:515-7.
  7. Lane A.H., Lee M.M., Fuller A.F.Jr et al. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999;73:51-5.
  8. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. Дис. ... д-ра мед. наук. М.; 2015: 254 с.
  9. de Wit R., Roberts J.T., Wilkinson P.M. et al. Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in GoodPrognosis Germ Cell Cancer: A randomized trial of EORTC and MRC. J Clin Oncol 2001;1629- 40.
  10. Matei D., Brown J., Frazier L. Updates in the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ Book 2013;e210.
  11. Brown J., Friedlander M., Backes F.J. et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer 2014;24(9 Suppl 3):S48-54.
  12. Vazquez I., Rustin G.J. Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol 2013;25:539-45.
  13. NCCN Clinical Practice Guidelines. Ovarian cancer including fallopian tube cancer and primary teritoneal cancer. Version 1.2019. https://www.nccn.org/professionals/physi- cian_gls/pdf/ovarian.pdf.
  14. Vazquez I., Rustin G.J. Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol 2013;25:539-45.
  15. Wilson M.K., Fong P., Mesnage S. et al. Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up. Gynecol Oncol 2015;138:285-91.
  16. Prat J., Cao D., Carinelli S. et al. Teratoma (Chapter 1: Tumours of the ovary). In: Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H., editors. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. IARC: Lyon; 2014. p. 57-62.
  17. Low J.J., Perrin L.C., Crandon A.J., Hacker N.F. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000;89:391- 8.
  18. Чекини Д.А. Факторы прогноза и тактика лечения больных злокачественными герминогенными опухолями яичников. Дис. ... к-та мед. наук. М.; 2017. 140 с.
  19. Billmire D., Vinocur C., Rescorla F. et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an Intergroup study. J Pediatr Surg 2004;39:424-9.
  20. Solheim O., Ksrn J., Trope C.G. et al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Gynecol Oncol 2013;131:330-5.
  21. De Giorgi U., Pupi A., Florentini G. et al. FDG-PET in the management of germ cell tumor. Ann Oncol 2005;16Supple4:90-4.
  22. Lambertini M., Ceppi M., Poggio F. et al. Ovarian suppression using luteinizing hormone- releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a metaanalysis of randomized studies. Ann Oncol 2015;26:2408- 19.
  23. Brown J., Shvartsman H.S., Deavers M.T. et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004;22:3517-23.
  24. Mangili G., Sigismondi C., Lorusso D. et al. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 2017;28:333-8.
  25. Low J.J., Perrin L.C., Crandon A.J., Hacker N.F. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000;89:391- 8.
  26. Callegaro-Filho D., Gershenson D.M., Nick A.M. et al. Small cell carcinoma of the ovary- hypercalcemic type (SCCOHT): a review of 47 cases. Gynecol Oncol 2016;140:53-7.
  27. van Meurs H.S., van Lonkhuijzen L.R., Limpens J. et al. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol 2014;134:196-205. NCT01770301. https://clinicaltrials.gov/show/NCT01770301 (12 March 2018, date last accessed).
  28. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
  29. Mangili G., Sigismondi C., Lorusso D. et al. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 2017;28:333-8.
  30. Tandstad T., Cavallin-Stahl E., Dahl O. et al. One course of adjuvant BEP in clinical stage I, nonseminoma: Mature and expanded results from the SWENOTECA group. J Clin Oncol 2013;31(suppl):4553.
  31. De la Motte Rouge T., Pautier яичников (клинико-морфологические особенности, лечение). Дис. ... д-ра мед. наук. М.; 2001. С. 265-285.
  32. Nasioudis D., Kanninen T.T., Holcomb K. et al. Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors. Gynecol Oncol 2017;145:243-7.
  33. Champion V., Williams S.D., Miller A. et al. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105:687- 94.
  34. Albers P. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I NSGCT: AUO trial AH 01/94 by the German Testicular Cancer Study. J Clin Oncol 2008;26(18):2966-72.
  35. Billmire D.F., Cullen J.W., Rescorla F.J. et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children"s Oncology Group. J Clin Oncol 2014;32:465-70.
  36. Mangili G., Sigismondi C., Gadducci A. et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer 2011;21:1414-21.
  37. Brown J., Friedlander M., Backes F.J. et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer 2014;24(9 Suppl 3):S48-54.
  38. Dark G.G., Bower M., Newlands E.S. et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997;15:620-4.
  39. Pectasides D., Pectasides E., Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev 2008;34:427-41.
  40. Williams S.D. Current management of ovarian germ cell tumors. Oncology (Williston Park) 1994;8:53-60.
  41. Williams S.D., Kauderer J., Burnett A.F. et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 2004;95:496-9.
  42. Loehrer P.J.Sr., Lauer R., Roth B.J. et al. Salvage therapy in reccurent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-6.
  43. Einhorn L.H. Chemotherapeutic and surgical strategies for germ cell tumors. Chest Surg Clin N Am 2002;12:695-706.
  44. Ray-Coquard P., Morice D., Lorusso J., Prat A., Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Supplement 4):iv1-iv18.
  45. Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. J Clin Oncol 2000;18(12):2413- 8.
  46. Mead G.M., Cullen M.H., Huddart R. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005;93:178-84.
  47. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500-4.
  48. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013 Apr;49(6):1374-403.
  49. Тюляндин С.А. Герминогенные опухоли яичников. Практическая онкология 2006;7(1):52- 61.
  50. Tewari K.S., Di Saia P.J. Ovulatory failure, fertility preservation and reproductive strategies in the setting of gynecologic and non-gynecologic malignancies. Eur J Gynaecol Oncol 2006;27:449-61.
  51. Kollmannsberger C., Beyer J., Liersch R. et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108-14.
  52. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germcell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448-53.
  53. Tomao F., Peccatori F., Del Pup L. et al. Special issues in fertility preservation for gynecologic malignancies. Crit Rev Oncol Hematol 2016;97:206-19.
  54. Allen J.C., Kirschner A., Scarpato K.R., Morgans A.K. Current management of refractory germ cell tumors and future directions. Curr Oncol Rep 2017;19:8.
  55. Gershenson D.M. Treatment of ovarian cancer in young women. Clin Obstet Gynecol 2012;55:65-74.
  56. Wilson M.K., Fong P., Mesnage S. et al. Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up. Gynecol Oncol 2015;138:285-91.
  57. Tao X., Sood A.K., Deavers M.T. et al. Anti-angiogenisis therapy with bevacizumab for patients with ovarian granulosa cell tumour. Gynecol Oncol 2009;114:431-6.
  58. Ray-Coquard I., Brown J., Harter P. et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer 2014;24(9Suppl3):S42-7.
  59. Brown J., Shvartsman H.S., Deavers M.T. et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004;22:3517-23.
  60. Homesley H.D., Bundy B.N., Hurteau J.A. et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies. Gynecol Oncol 1999;72:131-7.
  61. Gurumurthy M., Bryant A., Shnbhang S. et al. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary. Cochrane Database Syst Rev 2014;4.
  62. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715-27.
  63. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to postsurgery recovery? BMJ Open 2016;6(1):e007997. DOI: 10.1136/bmjopen-2015-007997.
  64. Hijazi Y., Gondal U., Aziz O. et al. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017;39:156-62. DOI: 10.1016/j.ijsu.2017.01.111.
  65. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015;22(13):4117-23. DOI: 10.1245/s10434-015- 4550-z.
  66. Carter J. Fast-Track Surgery in Gynaecology and Gynaecologic Oncology: A Review of a Rolling Clinical Audit. ISRN Surg 2012;2012(368014):19.
  67. Nelson G., Bakkum-Gamez J., Kalogera E. et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations - 2019 update. Int J Gynecol Cancer 2019.
  68. De Almeida E.P.M., de Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017;119(5):900-7.
  69. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010;210(4):491-5.
  70. Peedicayil A., Weaver A., Li X., Carey E. et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011;121(1):64-9.
  71. Swarm R., Abernethy A.P., Anghelescu D.L. et al. NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw 2010;8:1046-86.
  72. Ben-Arye E., Samuels N., Lavie O. Integrative medicine for female patients with gynecologic cancer. J Altern Complement Med 2018;24(9,10):881-9.
  73. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: a randomized study. Oncology 2014;87:114-24.
  74. Smits A., Lopes A., Bekkers R. et al. Body mass index and the quality of life of endometrial cancer survivors - a systematic review and meta-analysis. Gynecol Oncol 2015;137:180-7. DOI:10.1016/j.ygyno.2015.01.540.
  75. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42(7):1409- 26.
  76. Zhou Y., Chlebowski R., La Monte M.J. et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women"s Health Initiative. Gynecol Oncol 2014;133(1):4-10.
  77. Biglia N., Zanfagnin V., Daniele A. et al. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 2017;37(8):4005-15.
  78. Shaitelman S.F., Cromwell K.D., Rasmussen J.C., Stout N.L., Armer J.M., Lasinski B.B., Cormier J.N. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015 Jan-Feb;65(1):55-81. doi: 10.3322/caac.21253. Epub 2014 Nov 19. Erratum in: CA Cancer J Clin. 2015 May-Jun;65(3):252. PubMed PMID: 25410402; PubMed Central PMCID: PMC4808814.
  79. Borman Р. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018;64(3):179-197.
  80. Piller N., Douglass J., Heidenreich B., Moseley A. Placebo controlled trial of mild electrical stimulation. Journal of Lymphoedema. - 2010. - Vol 5, No 1. - P. 15-25.
  81. Грушина Т.И. Реабилитация в онкологии: физиотерапия. - М.: ГЭОТАР-Медиа, 2006. - 240 с.
  82. McNeely M.L., Peddle C.J., Yurick J.L., Dayes I.S., Mackey J.R. Conservative and dietary interventions for cancer-related lymphedema: A Systematic review and meta-analysis. Cancer. 2011 Mar 15;117(6):1136-48.
  83. Zhang Y.L., Huiling L., Yan L., Li H., Tian В. Effects of acupuncture on cancer-related fatigue: a meta-analysis // Supportive Care in Cancer. - 2018. - V. 26, Issue 2. - Pp. 415-425.
  84. Carmody J.F., Crawford S., Salmoirago-Blotcher E., Leung K., Churchill L., Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause. 2011 June;18(6):611-20. doi: 10.1097/gme.0b013e318204a05c.
  85. Ferrandina G., Petrillo M., Mantegna G., Fuoco G., Terzano S., Venditti L., Marcellusi A., De Vincenzo R., Scambia G. Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study. Gynecol Oncol. 2014 Jun;133(3):518- 25. doi: 10.1016/j.ygyno.2014.03.015.
  86. Donoyama N., Satoh T., Hamano T. et al. Physical effects of Anma therapy (Japanese massage) for gynecologic cancer survivors: A randomized controlled trial. Gynecol Oncol 2016;142:531- 538. Crossref, Medline, Google Scholar.
  87. Armbruster S.D., Song J., Bradford A. et al. Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol 2016;143:589-595. Crossref, Medline, Google Scholar.
  88. Huffman L.B., Hartenbach E.M., Carter J., Rash J.K., Kushner D.M. Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. Gynecol Oncol. 2016 Feb;140(2):359-68. doi: 10.1016/j.ygyno.2015.11.010. Epub 2015 Nov 7. PubMed PMID: 26556768; PubMed Central PMCID: PMC4835814.
  89. Dumoulin C., Cacciari L.P., Hay-Smith E.J.C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews 2018, Issue 10.
  90. Hu H., Xie Z.G., Qin W.L. Effect of electroacupuncture intervention at different phases of post- operation on bladder function in patients undergoing cervical cancer operation. Zhen Ci Yan Jiu 2013;38:64-67, 77. Medline, Google Scholar.
  91. Cannioto R.A., Moysich K.B. Epithelial ovarian cancer and recreational physical activity: A review of the epidemiological literature and implications for exercise prescription. Gynecol Oncol, 2015. 137(3): P. 559-73.
  92. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol. 2012;127(3):156-64. Epub 2012 Jan 31.
  93. Mustian K.M., Alfano C.M., Heckler C. et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961-968.
  94. Lawvere, Silvana. (2002). The effect of massage therapy in ovarian cancer patients. 10.1016/B978-0-7234-3217-3.50009-0.
  95. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H1., Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018 Feb 1;124(3):546-554. doi: 10.1002/cncr.31064.
  96. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289-1304.
  97. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019-1028.
  98. Muzi J.L., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., Sorenson L., Evans L., Kirchner S., Dashkoff C., Garrett K., Johnson N. Low-level laser therapy for chemotherapy- induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019- 9019.
  99. Rick O., von Hehn U., Mikus E., Dertinger H. & Geiger G. (2016). Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo- controlled phase-III study. Bioelectromagnetics, 38(2), 85-94.
  100. Kiling M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May;46(5):454-60. doi: 10.2340/16501977-1271.
  101. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8;9(9):e107418. doi: 10.1371/journal.pone.0107418. eCollection 2014.
  102. Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017 Apr 1;21(2):226-233. doi: 10.1188/17.CJON.226-233 .
  103. Avci P., Gupta G.K., Clark J., Wikonkal N. & Hamblin M.R. (2013). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in surgery and medicine, 46(2), 144-51.
  104. Spence Rosalind R. et al. Exercise and cancer rehabilitation: A systematic review. Cancer Treatment Reviews. - V. 36, Issue 2. - P. 185-194.
  105. Park S, Lee S, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Onkologie. 2011;34(8-9):416-20. doi: 10.1159/000331129.
  106. Tohya, T. Ovarian sex cord-stromal tumor, unclassified: case report of endocrinologic findings and review of the literature. International Journal of Gynecological Cancer, 2005, 15(6), 1153- 1155.
  107. Shaaban A. M. et al. Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features //Radiographics. - 2014. - Т. 34. - №. 3. - С. 777-801.
  108. Хохлова С. В., Давыдова И. Ю., Новикова Е. Г., Телетаева Г. М., Трякин А. А., Урманчеева А. Ф. практические рекомендации по лекарственному лечению неэпителиальных опухолей яичников // Злокачественные опухоли. - 2016. - № 4. Спецвыпуск 2. - С. 135-146.
  109. Johansen G. et al. Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study //Gynecologic oncology. - 2019. - Т. 155. - №. 2. - С. 287-293.
  110. Dark G. G. et al. Surveillance policy for stage I ovarian germ cell tumors //Journal of clinical oncology. - 1997. - Т. 15. - №. 2. - С. 620-624.
  111. Oliver RT, Mead GM, Rustin GJ et al Rindomized trial of carboplatin versus radiotherapy for stade I seminoma: mature results on relapse and contralaterated testis cancer rates in MRS TE19/EORTC 30982 study. JCO 2011; 29: 957-962.
  112. Satoh T. et al. Administration of standard-dose BEP regimen (bleomycin+ etoposide+ cisplatin) is essential for treatment of ovarian yolk sac tumour //European journal of cancer. - 2015- Т. 51. - №. 3. - С. 340-351.
  113. Bosl, G. J., Geller, N. L., Bajorin, D., Leitner, S. P., Yagoda, A., Golbey, R. B., ... Whitmore, W. (1989). A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors. The Journal of Urology, 141(6), 1499-1500. doi:10.1016/s0022- 5347(17)41358-9.
  114. Хохлова С.В, Давыдова И.Ю., Коломиец Л.А., Кузнецов В.В., Новикова Е.Г., Трякин А.А.и соавт. Практические рекомендации по лекарственному лечению злокачественных неэпителиальных опухолей яичников. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2019 (том 9). С. 177-191.
  115. Pico, J.-L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., . Biron, P. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Annals of Oncology, 16(7) 1152-1159. doi:10.1093/annonc/mdi228.
  116. Pautier P1, Gutierrez-Bonnaire M, Rey A et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2008 May-Jun;18(3):446-52.
  117. Stenman U. H. et al. Markers supplementing CA 125 in ovarian cancer //Annals of medicine. - 1995. - Т. 27. - №. 1. - С. 115-120.
  118. Yesilyurt H. et al. Parameters for predicting granulosa cell tumor of the ovary: a single center retrospective comparative study //Asian Pac J Cancer Prev. - 2014. - Т. 15. - № . 19. - С. 8447- 8450.
  119. Tohya, T. Ovarian sex cord-stromal tumor, unclassified: case report of endocrinologic findings and review of the literature. International Journal of Gynecological Cancer, 2005, 15(6), 1153- 1155.
  120. Tryakin A, Fedyanin M, Bulanov A, Kashia S, Kurmukov I, Matveev V, Fainstein I, Gordeeva O, Zakharova T, Tjulandin S. Dose-reduced first cycle of chemotherapy for prevention of life- threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018 Sep;144(9):1817- 1823. doi: 10.1007/s00432-018-2695-4.
  121. Aapro MS, Bohlius J, Cameron DA et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
  122. Хохлова С. В., Давыдова И. Ю., Коломиец Л. А., Кравец О. А., Крикунова Л. И., Кузнецов В. В. и соавт. Практические рекомендации по лекарственному лечению неэпителиальных опухолей яичников // Злокачественные опухоли. - 2015. - № 4, спецвыпуск. - С. 127-138. DOI: 10.18027/2224-5057-2015-4s-127-138
  123. С. А. Тюляндин, Д. А. Носов, Н. И. Переводчикова. Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ESMO) — М.: Издательская группа РОНЦ им. Н. Н. Блохина РАМН, 2010.— 436 с.
  124. Хохлова С. В, Давыдова И. Ю., Коломиец Л. А., Новикова Е. Г., Трякин А. А., Ур-манчеева А. Ф. Практические рекомендации по лекарственному лечению злокачественных неэпителиальных опухолей яичников // Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2017 (том 7). С. 146-157.
  125. Colombo, N., Peiretti, M., Garbi, A., Carinelli, S., Marini, C., & Sessa, C. (2012). Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(suppl 7), vii20-vii26. doi:10.1093/annonc/mds223
  126. Hardy R.D., Bell J.G., Nicely C.J. et al.Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005;96(3):865865
  127. Samant R., Fung M.F., Choan E. et al.Palliative radiotherapy for recurrent granulose cell tumor of the ovary: a report of 3 cases with radiological evidence of response. Gynecol Oncol 2006;102(2):406:406
  128. Елманов А.В. и соавт. Гранулезоклеточная опухоль яичников с множественными метастазами в кожу (клинический случай)./ Сибирский онкологический журнал. 2011. N5 (47)
  129. Kourie HR et al. Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report/ Onkologie. 2013;36(9):498-500. doi: 10.1159/000354635. Epub 2013 Aug 19.
  130. Freeman SA, Modesitt SC: Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol 2006;103:755-8.
  131. Kauppila A GnRH agonist analog therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment Gynecol Endocrinol. 1992 Dec;6(4):271-4.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*